2021 Q3 Form 10-Q Financial Statement

#000156459021055468 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q4 2020 Q3
Revenue $3.000M $6.400M $7.000K
YoY Change 42757.14% 91328.57% -12.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.221M $2.040M $1.070M
YoY Change 107.57% 2.51% -39.55%
% of Gross Profit
Research & Development $2.382M $2.530M $1.768M
YoY Change 34.73% -42.63% -51.73%
% of Gross Profit
Depreciation & Amortization $22.00K $20.00K $20.00K
YoY Change 10.0% 0.0%
% of Gross Profit
Operating Expenses $4.603M $4.570M $2.839M
YoY Change 62.13% -28.59% -47.75%
Operating Profit -$1.603M -$2.832M
YoY Change -43.4% -47.8%
Interest Expense -$6.000K -$70.00K -$240.0K
YoY Change -97.5% -74.07% -38.46%
% of Operating Profit
Other Income/Expense, Net -$1.084M -$160.0K $810.0K
YoY Change -233.83% -27.27% -640.0%
Pretax Income -$1.365M $1.610M -$2.250M
YoY Change -39.33% -123.4% -62.25%
Income Tax $100.0K $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$1.087M $1.130M -$1.533M
YoY Change -29.09% -125.69% -57.51%
Net Earnings / Revenue -36.23% 17.66% -21900.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$17.80K $22.09K -$31.72K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2020 Q4 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.57M $5.700M $1.800M
YoY Change 987.0% 216.67% -25.0%
Cash & Equivalents $19.60M $5.747M $1.827M
Short-Term Investments
Other Short-Term Assets $1.677M $1.300M $1.800M
YoY Change -6.83% 18.18% 50.0%
Inventory
Prepaid Expenses
Receivables $928.0K $158.0K $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $22.17M $7.215M $3.700M
YoY Change 499.22% 154.23% 3.73%
LONG-TERM ASSETS
Property, Plant & Equipment $724.0K $367.0K $900.0K
YoY Change -19.56% -20.39% 1856.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $8.539M $6.700M $2.500M
YoY Change 241.56% 168.0% 0.0%
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $9.263M $7.574M $3.300M
YoY Change 180.7% 17.83% -40.59%
TOTAL ASSETS
Total Short-Term Assets $22.17M $7.215M $3.700M
Total Long-Term Assets $9.263M $7.574M $3.300M
Total Assets $31.43M $14.79M $7.000M
YoY Change 349.06% 59.61% -23.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.663M $1.925M $5.700M
YoY Change -18.19% -13.75% -17.39%
Accrued Expenses $176.0K $200.0K $100.0K
YoY Change 76.0% 100.0% 0.0%
Deferred Revenue $35.00K $31.00K
YoY Change 0.0%
Short-Term Debt $0.00 $84.00K $334.0K
YoY Change -100.0% -41.67% -6.7%
Long-Term Debt Due $636.0K $100.0K $2.400M
YoY Change -73.5% -98.39% -67.57%
Total Short-Term Liabilities $5.510M $6.390M $8.300M
YoY Change -33.61% -52.25% -42.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $2.859M $50.00K $4.500M
YoY Change -36.47% -80.77% 1630.77%
Total Long-Term Liabilities $2.859M $50.00K $4.500M
YoY Change -36.47% -80.77% 1630.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.510M $6.390M $8.300M
Total Long-Term Liabilities $2.859M $50.00K $4.500M
Total Liabilities $52.98M $11.00M $58.40M
YoY Change -9.28% -39.27% 207.32%
SHAREHOLDERS EQUITY
Retained Earnings -$259.0M -$290.0M
YoY Change 24.2%
Common Stock $209.2M
YoY Change 13.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$21.55M -$80.10M -$51.37M
YoY Change
Total Liabilities & Shareholders Equity $31.43M $14.79M $7.000M
YoY Change 349.06% 59.61% -23.26%

Cashflow Statement

Concept 2021 Q3 2020 Q4 2020 Q3
OPERATING ACTIVITIES
Net Income -$1.087M $1.130M -$1.533M
YoY Change -29.09% -125.69% -57.51%
Depreciation, Depletion And Amortization $22.00K $20.00K $20.00K
YoY Change 10.0% 0.0%
Cash From Operating Activities -$3.594M -$2.210M -$5.440M
YoY Change -33.93% -62.41% -12.12%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.33M 6.130M 870.0K
YoY Change 1316.67% 16.1% -87.32%
NET CHANGE
Cash From Operating Activities -3.594M -2.210M -5.440M
Cash From Investing Activities 0.000
Cash From Financing Activities 12.33M 6.130M 870.0K
Net Change In Cash 8.731M 3.920M -4.570M
YoY Change -291.05% -685.07% -566.33%
FREE CASH FLOW
Cash From Operating Activities -$3.594M -$2.210M -$5.440M
Capital Expenditures $0.00
Free Cash Flow -$2.210M
YoY Change -61.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
115000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M12D
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1009000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
676000
CY2020Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
2871000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2382000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
84000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6390000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1603000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
50000
CY2020Q4 us-gaap Liabilities
Liabilities
10996000
CY2020Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
83895000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
209161000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-290036000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-80102000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14789000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1768000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
4603000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2839000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2832000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1084000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26111000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9731000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
47000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-16000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15788000
vtvt Proceeds From Issuance Of Common Stock To Related Party
ProceedsFromIssuanceOfCommonStockToRelatedParty
7000000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-996000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5747000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4277000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-51372000
us-gaap Profit Loss
ProfitLoss
-8248000
us-gaap Profit Loss
ProfitLoss
-14409000
us-gaap Depreciation
Depreciation
67000
vtvt Issuance Of Class A Common Stock Under Atm Offering
IssuanceOfClassACommonStockUnderATMOffering
9731000
vtvt Stock Issued During Period Value Conversion Of Convertible Securities Related Party
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedParty
7000000
us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
-10192000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-47823000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1087000
CY2021Q3 vtvt Issuance Of Class A Common Stock Under Atm Offering
IssuanceOfClassACommonStockUnderATMOffering
11689000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-21545000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-69528000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1533000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
171000
CY2020Q3 vtvt Issuance Of Class A Common Stock Under Atm Offering
IssuanceOfClassACommonStockUnderATMOffering
2451000
CY2020Q3 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
17067000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-51372000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-80102000
us-gaap Net Income Loss
NetIncomeLoss
-5936000
vtvt Issuance Of Class A Common Stock Under Atm Offering
IssuanceOfClassACommonStockUnderATMOffering
17024000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
47000
vtvt Issuance Of Class A Common Stock Under Lpc Agreement
IssuanceOfClassACommonStockUnderLPCAgreement
9087000
us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
36973000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-21545000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-49023000
us-gaap Net Income Loss
NetIncomeLoss
-9625000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
737000
us-gaap Depreciation
Depreciation
72000
us-gaap Share Based Compensation
ShareBasedCompensation
1362000
us-gaap Share Based Compensation
ShareBasedCompensation
737000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1814000
vtvt Change In Fair Value Of Warrants Related Party
ChangeInFairValueOfWarrantsRelatedParty
-611000
vtvt Change In Fair Value Of Warrants Related Party
ChangeInFairValueOfWarrantsRelatedParty
114000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
340000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
770000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
367000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
781000
vtvt Increase Decrease In Long Term Deposits
IncreaseDecreaseInLongTermDeposits
-444000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1514000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1352000
vtvt Accreted Interest On Debt
AccretedInterestOnDebt
750000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-178000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12891000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
887000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
500000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
335000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3893000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26710000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13338000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13819000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2450000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-259000000.0
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19600000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19566000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1827000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-1465000
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-378000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A Common Stock, the fair value of the Class B Common Stock, the useful lives of property and equipment, the fair value of derivative liabilities, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two and three customers represented 100% of the revenue earned during the three months and nine months ended September 30, 2021, respectively.  Revenue for the three and nine months ended September 30, 2020 was insignificant.</p>
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2021Q3 vtvt Adjustments To Transaction Price For Performance Obligations
AdjustmentsToTransactionPriceForPerformanceObligations
0
vtvt Adjustments To Transaction Price For Performance Obligations
AdjustmentsToTransactionPriceForPerformanceObligations
0
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
35000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
31000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
9000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1009000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
44000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1040000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
4296594
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.42
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4453357
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
70000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.56
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
20833
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
28121
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.00
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4474403
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.32
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2164063
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.68
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
474000
CY2021Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
8539000
CY2020Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
6725000
CY2021Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.215
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.131
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.131
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
64000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
261000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
268000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
275000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
23000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
891000
CY2021Q3 vtvt Operating Leases Imputed Interest
OperatingLeasesImputedInterest
175000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
716000
CY2021Q3 vtvt Redeemable Noncontrolling Interest Temporary Equity Redemption Value
RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
44600000
CY2020Q4 vtvt Redeemable Noncontrolling Interest Temporary Equity Redemption Value
RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
83900000
CY2020Q4 vtvt Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
250000000
CY2021Q2 vtvt Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
350000000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1087000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1533000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5936000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9625000
CY2021Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
2773000
CY2021Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
-3860000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-720000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2312000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4784000
vtvt Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-5936000
vtvt Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-9625000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29582766
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29583915

Files In Submission

Name View Source Status
0001564590-21-055468-index-headers.html Edgar Link pending
0001564590-21-055468-index.html Edgar Link pending
0001564590-21-055468.txt Edgar Link pending
0001564590-21-055468-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g21svogyxmcu000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtvt-10q_20210930.htm Edgar Link pending
vtvt-10q_20210930_htm.xml Edgar Link completed
vtvt-20210930.xsd Edgar Link pending
vtvt-20210930_cal.xml Edgar Link unprocessable
vtvt-20210930_def.xml Edgar Link unprocessable
vtvt-20210930_lab.xml Edgar Link unprocessable
vtvt-20210930_pre.xml Edgar Link unprocessable
vtvt-ex311_9.htm Edgar Link pending
vtvt-ex312_7.htm Edgar Link pending
vtvt-ex321_6.htm Edgar Link pending
vtvt-ex322_11.htm Edgar Link pending